AJOVista LLC Invests $76,000 in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

AJOVista LLC purchased a new stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,695 shares of the company’s stock, valued at approximately $76,000.

Several other institutional investors also recently bought and sold shares of the business. Inspire Investing LLC raised its position in Deciphera Pharmaceuticals by 10.4% in the third quarter. Inspire Investing LLC now owns 27,532 shares of the company’s stock valued at $350,000 after purchasing an additional 2,583 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after purchasing an additional 997 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at approximately $1,167,000. Principal Financial Group Inc. grew its position in shares of Deciphera Pharmaceuticals by 10.3% during the third quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock worth $232,000 after buying an additional 1,699 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $287,000. 70.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 29th. Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. JPMorgan Chase & Co. boosted their target price on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, March 20th. Finally, Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $9.00 to $26.00 in a research report on Tuesday, April 30th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.17.

Deciphera Pharmaceuticals Stock Performance

NASDAQ DCPH remained flat at $25.38 on Friday. 1,940,709 shares of the company’s stock traded hands, compared to its average volume of 3,485,766. The firm’s 50 day simple moving average is $16.56 and its 200-day simple moving average is $14.83. Deciphera Pharmaceuticals, Inc. has a 1 year low of $9.90 and a 1 year high of $25.47.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The company had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.60) earnings per share. As a group, equities research analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current fiscal year.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.